Skip to main content
Genscript Biotech Corporation logo

Genscript Biotech Corporation — Investor Relations & Filings

Ticker · 1548 ISIN · KYG3825B1059 LEI · 529900YIYUOJOXSAE372 HKEX Manufacturing
Open in API
Filings indexed 819 across all filing types
Latest filing 2025-10-03 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 1548

About Genscript Biotech Corporation

http://www.genscript.com/investor-relat…

Genscript Biotech Corporation is a world-leading technology and service provider specializing in life science research and manufacturing. The company offers a comprehensive portfolio of services and products essential for fundamental life science research, translational biomedical research, and early drug discovery and development. Core offerings include custom synthesis of genes, peptides, proteins, and antibodies, alongside molecular cloning and oligonucleotide production. GenScript also provides Contract Development and Manufacturing Organization (CDMO) solutions for innovative therapies through its specialized subsidiaries. The corporation leverages biotechnology and AI-driven approaches to advance life science solutions.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2025
Share Issue/Capital Change Classification · 1% confidence The document is a Hong Kong Exchange Listing Rules Chapter 19B monthly return (Form FF301) reporting movements in authorised/registered share capital, issued shares, and share options exercise for the month ended 30 September 2025. It details a change in the company’s capital structure (issuance of 220,000 new shares upon exercise of share options) rather than being an earnings release, AGM material, or general regulatory notice. This falls squarely under announcements of share issues or other capital changes.
2025-10-03 English
GRANT OF SHARE AWARDS
Director's Dealing Classification · 1% confidence The document is an equity grant announcement made under the Hong Kong Listing Rules, disclosing the grant of restricted share units to employees and to an executive director. This falls under insider personal share transactions by executives (share awards are a form of director/executive dealing). Therefore, it best fits the “Director’s Dealing” category (DIRS).
2025-09-21 English
INTERIM REPORT 2025
Regulatory Filings
2025-09-11 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2025
Share Issue/Capital Change Classification · 1% confidence The document is a monthly return (Form FF301) submitted to the Hong Kong Stock Exchange reporting movements in authorized share capital, issued shares, treasury shares, share options, and other related share capital changes for the month. It details new share issues, option exercises, and capital movements under Chapter 19B of the Exchange Listing Rules. This is not a full financial report but an announcement of share capital changes. It best fits the “Share Issue/Capital Change” category (Code: SHA).
2025-09-03 English
ANNOUNCEMENT OF UNAUDITED CONSOLIDATED INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2025
Interim / Quarterly Report Classification · 1% confidence The document is an 'Announcement of Unaudited Consolidated Interim Results' for Genscript Biotech Corporation for the six months ended June 30, 2025. It contains comprehensive financial statements, including the Statement of Profit or Loss, Statement of Comprehensive Income, Statement of Financial Position, and Statement of Cash Flows, along with detailed notes. This meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H2 2025
2025-08-17 English
VOLUNTARY ANNOUNCEMENT: FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025 OF A LISTED ASSOCIATE - LEGEND BIOTECH CORPORATION
Report Publication Announcement Classification · 1% confidence The document is a voluntary Hong Kong Exchange announcement by GenScript Biotech Corporation informing investors that its listed associate, Legend Biotech Corporation, has filed a Form 6-K with the SEC containing its Q2 2025 results and business highlights. The announcement contains no financial data itself but directs readers to the full Form 6-K on the SEC website. This fits the definition of a Report Publication Announcement (RPA): an announcement regarding the release/publication of a report (Form 6-K), rather than the report content itself.
2025-08-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.